收费全文 | 158095篇 |
免费 | 32045篇 |
国内免费 | 2406篇 |
耳鼻咽喉 | 5277篇 |
儿科学 | 5678篇 |
妇产科学 | 2567篇 |
基础医学 | 4159篇 |
口腔科学 | 1667篇 |
临床医学 | 27668篇 |
内科学 | 48763篇 |
皮肤病学 | 7491篇 |
神经病学 | 15635篇 |
特种医学 | 6568篇 |
外国民族医学 | 2篇 |
外科学 | 41805篇 |
综合类 | 461篇 |
现状与发展 | 72篇 |
一般理论 | 7篇 |
预防医学 | 7770篇 |
眼科学 | 3416篇 |
药学 | 1380篇 |
中国医学 | 12篇 |
肿瘤学 | 12148篇 |
2024年 | 689篇 |
2023年 | 4800篇 |
2022年 | 1211篇 |
2021年 | 3126篇 |
2020年 | 6060篇 |
2019年 | 2212篇 |
2018年 | 7461篇 |
2017年 | 7408篇 |
2016年 | 8493篇 |
2015年 | 8476篇 |
2014年 | 15591篇 |
2013年 | 15806篇 |
2012年 | 5706篇 |
2011年 | 5704篇 |
2010年 | 10484篇 |
2009年 | 14388篇 |
2008年 | 6039篇 |
2007年 | 4302篇 |
2006年 | 6759篇 |
2005年 | 4022篇 |
2004年 | 3286篇 |
2003年 | 2263篇 |
2002年 | 2340篇 |
2001年 | 4109篇 |
2000年 | 3326篇 |
1999年 | 3484篇 |
1998年 | 3735篇 |
1997年 | 3542篇 |
1996年 | 3458篇 |
1995年 | 3287篇 |
1994年 | 2002篇 |
1993年 | 1639篇 |
1992年 | 1594篇 |
1991年 | 1610篇 |
1990年 | 1266篇 |
1989年 | 1382篇 |
1988年 | 1223篇 |
1987年 | 1062篇 |
1986年 | 1033篇 |
1985年 | 881篇 |
1984年 | 671篇 |
1983年 | 618篇 |
1982年 | 578篇 |
1981年 | 490篇 |
1980年 | 427篇 |
1979年 | 423篇 |
1978年 | 416篇 |
1977年 | 490篇 |
1975年 | 362篇 |
1972年 | 372篇 |
The development of Laparoscopic Linear Endostaplers (LLES) is crucial in minimally invasive approaches in bariatric surgery, but there have been very few published studies comparing 6-row LLES in Laparoscopic Sleeve Gastrectomy (LSG). The objective of this study was to compare two 6-row LLES in LSG.
MethodsA total of 60 patients were prospectively randomized to undergo LSG with either Medtronic Endo GIA? Tri-Staple technology (MTS) or AEON ? Endostapler(Lexington Medical) LLES. The measured parameters included patient demographics, comorbidity indices, LLES and specimen characteristics, postoperative symptoms, hospital stay, and total adverse events (AEs). Intraoperative bleeding was evaluated using five laparoscopic and corresponding endoscopic images of staple line before clip application, compared with a 1–5 Visual Analogue Scale (VAS), assessed by an independent bariatric surgeon who was blinded to the LLES used. Images of all cases were reviewed on the same day to increase test–retest reliability.
ResultsBoth groups were similar in patient demographics. Compared to MTS, AEON LLES group had significantly lower bleeding VAS scores in 4/5 laparoscopic images (pre-pyloric: 1.7?±?0.7 vs. 2.36?±?0.76, p?=?0.0007, mid-sleeve: 1.46?±?0.62 vs. 1.86?±?0.68, p?=?0.019, proximal sleeve: 1.6?±?0.77 vs. 2.0?±?0.83, p?=?0.038, gastro-esophageal junction: 1.43?±?0.67 vs. 1.86?±?0.77, p?=?0.014) and 3/5 endoscopic images (pre-pyloric: 1.56?±?0.56 vs. 2.36?±?0.76, p?=?0.006, incisura: 1.66?±?0.54 vs. 2.0?±?0.52, p?=?0.021, mid-sleeve: 1.63?±?0.49 vs. 2.0?±?0.45, p?=?0.005). There was no statistical difference in other parameters.
ConclusionBoth devices were equally safe and effective in terms of LLES and specimen characteristics, patient symptoms, hospital stay, and AEs. Bleeding VAS scores were significantly lower, favoring the AEON LLES.
Graphical abstract 相似文献Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.